Cargando…
Response to “Quantitative Clinical Pharmacology INPUT to SARS‐CoV‐2 Therapeutics Should be Based on Robust Data”
Autores principales: | Garcia‐Cremades, Maria, Solans, Belen P., Hughes, Emma, Ernest, Jacqueline P., Wallender, Erika, Savic, Radojka M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267305/ https://www.ncbi.nlm.nih.gov/pubmed/32348544 http://dx.doi.org/10.1002/cpt.1873 |
Ejemplares similares
-
Optimizing Hydroxychloroquine Dosing for Patients With COVID‐19: An Integrative Modeling Approach for Effective Drug Repurposing
por: Garcia‐Cremades, Maria, et al.
Publicado: (2020) -
Malaria PK/PD and the Role Pharmacometrics Can Play in the Global Health Arena: Malaria Treatment Regimens for Vulnerable Populations
por: Hughes, Emma, et al.
Publicado: (2021) -
Interplay among malnutrition, chemoprevention, and the risk of malaria in young Ugandan children: Longitudinal pharmacodynamic and growth analysis
por: Ali, Ali Mohamed, et al.
Publicado: (2023) -
A Quantitative Systems Pharmacology Consortium Approach to Managing Immunogenicity of Therapeutic Proteins
por: Kierzek, Andrzej M., et al.
Publicado: (2019) -
NIH Support for the Emergence of Quantitative and Systems Pharmacology
por: Rogers, M, et al.
Publicado: (2013)